The Top 100 Pharmaceutical Companies

The Top 100 Pharmaceutical Companies, determined by total sales in 2011 - see below for 2010 and  2009: They are listed in descending order with the sales in 2011 in $ million; Pfizer ...

Mitsubishi Tanabe

Mitsubishi Tanabe is a top pharmaceutical company based in Tokyo, Japan. The company was formed in October, 2007 with the merger of Tanabe Seiyaku Co., Ltd. and Mitsubishi Pharma (formed in 2001 with...

Japanese approval for Mitsubishi Tanabe's teneligliptin

Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508) said Japan's Ministry of Health, Labor and Welfare approved a regulatory application for Tenelia teneligliptin to treat Type II diabetes. Mitsub...

Tanabe Mitsubishi Applies For DPP-4 Inhibitor Tenelia Combination Therapy

Tanabe Mitsubishi has applied for an additional indication for DPP-4 inhibitor 20mg Tenelia tablets (teneligliptin hydrobromide hydrate) for use in combination therapy, the company announced on Feb. 2...

Mitsubishi Tanabe: Company Profile

Mitsubishi Tanabe, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years. Return to top 50 pharma list Summary Website: Mits...

Covagen inks $146 million pact with Mitsubishi Tanabe Pharma

Covagen has entered into a strategic research collaboration and license agreement with Mitsubishi Tanabe Pharma Corporation and its fully owned subsidiary Tanabe Research Laboratories. Under the agree...

Dezima Pharma in-licenses CETP inhibitor program from Mitsubishi Tanabe Pharma

Dezima Pharma announced the in-licensing of a cholesteryl ester transfer protein inhibitor DEZ-001 from Mitsubishi Tanabe Pharma. Terms of the deal were not disclosed. Related items: Report: Partneri...

Japan uptake of Simponi music to Mitsubishi Tanabe's ears

Simponi (golimumab) is so far living up to Mitsubishi Tanabe Pharma's (MTP) expectations in Japan, with sales of the monoclonal antibody for rheumatoid arthritis coming in slightly ahead of the firm'...

AnGes' lead therapeutic set for progress following US Mitsubishi Tanabe deal

The Japanese bioventure AnGes MG has reached a basic agreement with a new partner that will allow the delayed development programme for its most advanced pipeline project to move forward. The deal giv...

Neuroprotective effects of a novel water-soluble poly(ADP-ribose) polymerase-1 inhibitor, MP-124, in in vitro and in vivo models of cerebral ischemia.

Cerebral ischemia induces excessive activation of poly(ADP-ribose) polymerase-1 (PARP-1), leading to neuronal cell death and the development of post-ischemic dysfunction. Blockade of PARP-related sign...

Fused bicyclic heteroarylpiperazine-substituted l-prolylthiazolidines as highly potent DPP-4 inhibitors lacking the electrophilic nitrile group.

Hypoglycemic agents with a mechanism of depeptidyl peptidase IV (DPP-4) inhibition are suitable for once daily oral dosing. It is difficult to strike a balance between inhibitory activity and duration...

Establishment of infectious HCV virion-producing cells with newly designed full-genome replicon RNA.

Hepatitis C virus (HCV) replicon systems enable in-depth analysis of the life cycle of HCV. However, the previously reported full-genome replicon system is unable to produce authentic virions. On the...

Decoration of fibrinogen γ-chain peptide on adenosine diphosphate-encapsulated liposomes enhances binding of the liposomes to activated platelets.

For the purpose of efficient hemostasis, we previously developed ADP-encapsulated liposomes modified with a dodecapeptide (HHLGGAKQAGDV, H12), H12-(ADP)Lipo. This liposome actually enhanced platelet a...

Anticoagulation With Argatroban for Elective Percutaneous Coronary Intervention: Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationship of Coagulation Parameters.

The synthetic direct thrombin inhibitor argatroban has a rapid onset and offset of anticoagulation. However, there are no data about the pharmacokinetic-pharmacodynamic (PK-PD) relationship of argatro...